Impairment Risk from Changes in the Business Environment and Revisions to Business Plans
First written in FY2016-Q3. 14 of 35 entries say "Worsened", first in FY2016. Latest entry: 2026-07-31.
Otsuka Holdings moved to the "Worse" side of this theme in 2016, 5 years before the typical company in this theme (2021).
The whole theme swung hardest in 2020: 51 of 96 companies on the "Worse" side.
26 other companies' latest entry also says "Worsened".
- 2026-07-31WorsenedEarnings
「Impairment loss 531 4,052 3,521 662.5%」
Impairment losses increased from ¥531 million in the same period of the previous year to ¥4,052 million. - FY2026-H1WorsenedAnnual report
「Impairment losses 531 4,052 3,521 662.5%」
Impairment losses for the six months ended the interim period were ¥4,052 million, up 662.5% from ¥531 million in the same period of the previous year. Although the level was below that of the large impairment losses in the previous fiscal year, impairment losses have increased again. - FY2025MitigatedAnnual report
「Impairment losses recognized during the consolidated fiscal year totaled ¥26,426 million.」
Impairment losses decreased 79.0% from ¥126,040 million in the previous fiscal year to ¥26,426 million. Although impairment losses arose at Daiya Foods and elsewhere, they were lower than the large impairment losses related to AVP-786 and other items in the previous fiscal year. - FY2025-H1MitigatedAnnual report
「There were no material impairment losses requiring disclosure during the six months ended the interim period.」
Whereas impairment losses of ¥104,076 million, mainly related to AVP-786, were recognized in the same period of the previous year, it states that there were no material impairment losses requiring disclosure during the six months ended the interim period. - FY2024MaterialisedAnnual report
「The ¥119,682 million in impairment losses recognized in the Medical business during the consolidated fiscal year comprised ¥3,569 million related to property, plant and equipment and ¥116,112 million related to intangible assets, mainly ¥102,839 million related to AVP-786 and ¥11,119 million related to digital medicine assets.」
In addition to the discontinuation of AVP-786 development, impairment losses arose on digital medicine assets following the decision to end US sales of Abilify MyCite and other factors. - FY2024-H1MaterialisedAnnual report
「Impairment losses of ¥104,076 million were recognized during the six months ended the second quarter, including ¥103,886 million in the Medical business. Medical business impairment losses mainly comprised ¥103,293 million related to AVP-786.」
Following the results of the Phase 3 trial for AVP-786, development was discontinued and the carrying amount of in-process research and development was reduced to zero, its recoverable amount. Impairment losses increased from ¥28,929 million in the same period of the previous year to ¥104,076 million. - FY2024-Q1MitigatedAnnual report
「Impairment losses were ¥125 million, down 40.8% year on year.」
Impairment losses decreased from ¥211 million in the same quarter of the previous year to ¥125 million, down 40.8%. - FY2023WorsenedAnnual report
「Impairment losses were ¥172,419 million, up 315.3% year on year.」
Impairment losses increased substantially from ¥41,521 million in the previous fiscal year to ¥172,419 million. Impairment losses arose on AVP-786, products partnered with Sumitomo Pharma Co.,Ltd., Daiya Foods and other items. - FY2023-Q3WorsenedAnnual report
「Impairment losses of ¥57,172 million were recognized during the nine months ended the third quarter, comprising ¥30,201 million in the Medical business, ¥23,459 million in the Nutraceuticals business and ¥28,242 million for the three months ended the third quarter.」
Impairment losses increased from ¥30,697 million in the same period of the previous year to ¥57,172 million. Impairment losses of ¥23,106 million were recognized on products partnered with Sumitomo Pharma Co.,Ltd. and ¥22,229 million at Daiya Foods. - FY2023-Q2MaterialisedAnnual report
「In the Nutraceuticals business, mainly at Daiya Foods, which develops, manufactures and sells plant-based foods in North America, profitability declined due to intensified competition in the North American dairy-alternative cheese market and other factors. The carrying amount of assets related to Daiya Foods was reduced to the recoverable amount, and an impairment loss of ¥21,706 million was recognized, comprising ¥12,194 million in goodwill, ¥2,377 million in trademarks and distribution rights and other items, and ¥7,134 million in other intangible assets.」
An impairment loss of ¥21,706 million was recognized following lower profitability at Daiya Foods due to intensifying competition. Impairment risk from changes in the business environment and revisions to business plans has again materialized. - FY2023-Q1MitigatedAnnual report
「There were no material impairment losses requiring disclosure during the three months ended the first quarter.」
Whereas an impairment loss of ¥23,584 million related to badadeustat was recognized in the first quarter of the previous fiscal year, it states that there were no material impairment losses requiring disclosure in the first quarter. - FY2022WorsenedAnnual report
「The ¥38,287 million in impairment losses recognized in the Medical business during the consolidated fiscal year comprised … impairment losses related to badadeustat, which was under development for an indication for anemia due to chronic kidney disease.」
Total impairment losses were ¥41,521 million, including impairment losses on badadeustat, for which a Complete Response Letter was received from the FDA, with the carrying amount of in-process research and development and other items reduced to zero. - FY2022-Q3WorsenedAnnual report
「As a result of concentrating the Medical Devices business on priority projects, impairment losses were recognized during the three months ended the third quarter on some property, plant and equipment and intangible assets, mainly trademarks and distribution rights, resulting in total impairment losses of ¥30,697 million for the nine months ended the third quarter.」
New asset impairments arose as the Medical Devices business concentrated on priority projects, bringing impairment losses for the nine months ended the third quarter to ¥30,697 million. - FY2022-Q2MaterialisedAnnual report
「An impairment loss of ¥24,356 million related to badadeustat and other items was recognized, but」
Impairment losses for the six months ended the second quarter totaled ¥24,356 million, of which ¥23,584 million related to badadeustat. As in the previous quarter, impairment related to the business plan and approval outlook has materialized. - FY2022-Q1MaterialisedAnnual report
「In the Medical business, following receipt from the FDA of a Complete Response Letter stating that the application data for badadeustat, which was under review for indications for anemia due to chronic kidney disease in dialysis and pre-dialysis patients, could not support approval, the carrying amounts of in-process research and development recognized as intangible assets and other related assets were reduced to zero, and an impairment loss of ¥23,584 million was recognized.」
A Complete Response Letter was received from the FDA for badadeustat, and an impairment loss of ¥23,584 million was recognized by reducing the carrying amount of in-process research and development and other items to zero. Impairment risk associated with revisions to business plans and profitability has again materialized. - FY2021MitigatedAnnual report
「The ¥5,376 million in impairment losses recognized in the Medical business during the consolidated fiscal year comprised ¥555 million related to property, plant and equipment, ¥3,999 million related to intangible assets and ¥821 million related to assets held for sale.」
Full-year impairment losses decreased 75.2% from ¥26,110 million in the previous fiscal year to ¥6,479 million. However, impairment losses arose due to, among other factors, revisions to the probability of success following delays in certain pipeline research and development projects. - FY2021-Q3MitigatedAnnual report
「There were no impairments of material assets.」
There were no impairments of material assets during the nine months ended the third quarter, and the large impairment losses related to guadecitabine and badadeustat recognized in the same period of the previous year did not recur. - FY2021-Q2WorsenedAnnual report
「Impairment losses were ¥49 million, down 86.9% year on year.」
Impairment losses for the six months ended the second quarter were ¥309 million, an increase of ¥260 million, or 525.7%, from ¥49 million in the same period of the previous year. - FY2021-Q1MaterialisedAnnual report
「Impairment losses － 51 51 －」
An impairment loss of ¥51 million was recognized in the first quarter, with a new impairment loss arising from zero in the same quarter of the previous year. - FY2020WorsenedAnnual report
「The ¥25,972 million in impairment losses recognized in the Medical business during the consolidated fiscal year comprised … ¥25,153 million related to intangible assets.」
Impairment losses increased from ¥13,476 million in the previous fiscal year to ¥26,110 million. Impairment losses on intangible assets of ¥10,644 million related to the discontinuation of guadecitabine development and ¥14,050 million related to the reassessment of the badadeustat business plan were recognized. - FY2020-Q3WorsenedAnnual report
「Impairment losses of ¥25,102 million (¥25,052 million for the three months ended the third quarter) were recognized during the nine months ended the third quarter.」
Impairment losses increased substantially from ¥400 million in the same period of the previous year to ¥25,102 million. Impairment losses on intangible assets of ¥10,723 million related to the discontinuation of guadecitabine development and ¥14,050 million related to the reassessment of the badadeustat business plan were recognized. - FY2020-Q2MitigatedAnnual report
「Impairment losses were ¥49 million, down 86.9% year on year.」
Impairment losses for the six months ended the second quarter decreased from ¥377 million in the same period of the previous year to ¥49 million, indicating a lower level of impairment risk materialization. - FY2020-Q1MitigatedAnnual report
「Impairment losses 66 － △66 △100.0%」
There were no impairment losses in the first quarter, a 100% decrease from ¥66 million in the same quarter of the previous year. - FY2019MitigatedAnnual report
「Impairment losses for the consolidated fiscal year were ¥13,476 million, down 61.2% year on year.」
Impairment losses decreased 61.2% from ¥34,742 million in the previous fiscal year to ¥13,476 million. However, impairment losses continued to arise during the fiscal year, mainly in the Medical business. - FY2019-Q3MitigatedAnnual report
「There were no material impairment losses requiring disclosure during the nine months ended the third quarter.」
There were no material impairment losses, and impairment losses for the nine months ended the third quarter were ¥400 million, down 98.4% year on year. - FY2019-Q2MitigatedAnnual report
「Impairment losses for the six months ended the second quarter were ¥377 million, down 96.7% year on year.」
Impairment losses for the six months ended the second quarter were ¥377 million, down 96.7% from ¥11,467 million in the same period of the previous year. It also states that there were no material impairment losses. - FY2019-Q1MitigatedAnnual report
「Impairment losses 419 66 △352 △84.1%」
Impairment losses in the first quarter were ¥66 million, down 84.1% from ¥419 million in the same quarter of the previous year. Impairment risk materialized at a lower level in the quarter than in the same quarter of the previous year. - FY2018WorsenedAnnual report
「The ¥33,884 million in impairment losses recognized in the Medical business during the consolidated fiscal year comprised ¥850 million related to property, plant and equipment and ¥33,034 million related to intangible assets.」
Impairment losses in the Medical business increased from ¥26,812 million in the previous fiscal year to ¥33,884 million. Impairment losses on intangible assets were recognized for ONZETRA Xsail, centanafadine and guadecitabine due to the termination of license agreements or the originally projected profitability no longer being expected. - FY2018-Q3WorsenedAnnual report
「Research and development expenses for the nine months ended the third quarter included impairment losses of ¥22,515 million (¥13,742 million for the three months ended the third quarter) due to the originally projected profitability no longer being expected, among other factors.」
Impairment losses on intangible assets of ¥8,444 million and ¥12,845 million, respectively, were recognized for centanafadine and guadecitabine due to lower expected profitability. - FY2018-Q2MaterialisedAnnual report
「Research and development expenses for the six months ended the second quarter included impairment losses of ¥8,772 million (¥8,372 million for the three months ended the second quarter) due to the originally projected profitability no longer being expected, among other factors.」
An impairment loss of ¥8,772 million was recognized for centanafadine under development because its originally projected profitability was no longer expected. - FY2017RestatedAnnual report
「The ¥26,812 million in impairment losses recognized in the Medical business during the consolidated fiscal year comprised ¥37 million related to property, plant and equipment, ¥1,459 million related to goodwill and ¥25,315 million related to intangible assets.」
Although impairment losses decreased from ¥32,133 million in the previous fiscal year to ¥28,847 million, an impairment loss of ¥23,104 million was recognized on intangible assets due to the lower profitability of ONZETRA Xsail, indicating that the risk associated with revisions to business plans and profitability continues to materialize. - FY2017-Q3WorsenedAnnual report
「Selling, general and administrative expenses for the nine months ended the third quarter included impairment losses of ¥25,031 million (¥1,755 million for the three months ended the third quarter) due to the originally projected profitability no longer being expected, among other factors. The main impairment loss for the nine months ended the third quarter was ¥23,047 million related to intangible assets for ONZETRA Xsail (generic name: sumatriptan), a treatment for acute migraine in the Medical business, because its originally projected profitability was no longer expected.」
Impairment losses associated with revisions to business plans and profitability totaled ¥25,031 million for the nine months ended the third quarter, with the ¥23,047 million impairment related to ONZETRA Xsail as the main factor, indicating that the risk continues to materialize and expand. - FY2017-Q2WorsenedAnnual report
「Selling, general and administrative expenses for the six months ended the second quarter included impairment losses of ¥23,276 million (¥23,276 million for the three months ended the second quarter) due to the originally projected profitability no longer being expected, among other factors. The main impairment loss related to ONZETRA Xsail (generic name: sumatriptan), a treatment for acute migraine in the Medical business, because its originally projected profitability was no longer expected.」
An additional impairment loss of ¥23,276 million was recognized, mainly due to the lower expected profitability of ONZETRA Xsail, indicating that impairment risk associated with revisions to business plans and profitability continues to materialize. - FY2016WorsenedAnnual report
「Impairment losses recognized during the consolidated fiscal year totaled ¥32,133 million.」
Impairment losses increased to ¥32,133 million for the full year, comprising ¥21,051 million in the Medical business, ¥5,986 million in the Nutraceuticals business and ¥4,638 million in the Consumer business, among others. - FY2016-Q3MaterialisedAnnual report
「For property, plant and equipment, goodwill and other intangible assets, certain consolidated subsidiaries revised their business plans following changes in the business environment in each business segment. As a result, the originally projected earnings were no longer expected, and ¥7,017 million was recognized as an impairment loss in extraordinary losses.」
An impairment loss of ¥7,017 million was recognized as a result of changes in the business environment and revisions to business plans.